SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-65676"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-65676" > The effect of atorv...

The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity

Hukkanen, J. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Puurunen, J. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Hyötyläinen, Tuulia, 1971- (författare)
Steno Diabetes Center, Gentofte, Denmark
visa fler...
Savolainen, M. J. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Ruokonen, A. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Morin-Papunen, L. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Oresic, Matej, 1967- (författare)
Steno Diabetes Center, Gentofte, Denmark
Piltonen, T. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland
Tapanainen, J. S. (författare)
University of Oulu, Oulu, Finland; Oulu University Hospital, Oulu, Finland; University of Helsinki, Helsinki, Finland; Helsinki University Hospital, Helsinki, Finland
visa färre...
 (creator_code:org_t)
2015-07-22
2015
Engelska.
Ingår i: British Journal of Clinical Pharmacology. - : Blackwell Publishing. - 0306-5251 .- 1365-2125. ; 80:3, s. 473-479
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Aims: Atorvastatin is known to both inhibit and induce the cytochrome P450 3A4 (CYP3A4) enzyme in vitro. Some clinical studies indicate that atorvastatin inhibits CYP3A4 but there are no well-controlled longer term studies that could evaluate the inducing effect of atorvastatin. We aimed to determine if atorvastatin induces or inhibits CYP3A4 activity as measured by the 4β-hydroxycholesterol to cholesterol ratio (4βHC : C).Methods: In this randomized, double-blind, placebo-controlled 6 month study we evaluated the effects of atorvastatin 20mg day1 (n=15) and placebo (n = 14) on oxysterol concentrations and determined if atorvastatin induces or inhibits CYP3A4 activity as assessed by the 4βHC : C index. The respective 25-hydroxycholesterol and 5α,6α- epoxycholesterol ratios were used as negative controls.Results: Treatment with atorvastatin decreased 4βHC and 5α,6α-epoxycholesterol concentrations by 40% and 23%, respectively. The mean 4βHC : C ratio decreased by 13% (0.214 ± 0.04 to 0.182 ± 0.04, P = 0.024, 95% confidence interval (CI) of the difference –0.0595, –0.00483) in the atorvastatin group while no significant change occurred in the placebo group. The difference in change of 4βHC : C between study arms was statistically significant (atorvastatin –0.032, placebo 0.0055, P = 0.020, 95% CI of the difference – 0.069, –0.0067). The ratios of 25-hydroxycholesterol and 5α,6α- epoxycholesterol to cholesterol did not change.Conclusions: The results establish atorvastatin as an inhibitor of CYP3A4 activity.Furthermore, 4βHC : C is a useful index of CYP3A4 activity, including theconditions with altered cholesterol concentrations.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Nyckelord

25-hydroxycholesterol
4β-hydroxycholesterol
6α-epoxycholesterol
atorvastatin
desmosterol
pregnane X receptor

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy